摘要
目的探究重组人尿激酶原联合替罗非班治疗急性心肌梗死经皮冠状动脉介入治疗(PCI)患者的临床效果。方法选取2021年5月至2022年5月我院收治的100例急性心肌梗死PCI术患者,根据治疗方案的差异将其分为对照组和观察组,各50例。对照组采用PCI术+常规药物+替罗非班治疗,观察组在对照组基础上采用重组人尿激酶原治疗。比较两组的临床疗效、心功能指标[左心室射血分数(LVEF)、左心室舒张末期内径(LVEDD)、左心室收缩末期内径(LVESD)]、心肌酶指标[肌酸激酶(CK)、肌酸激酶同工酶(CK-MB)、乳酸脱氢酶(LDH)]及PCI术后不良心血管事件发生情况。结果观察组的治疗总有效率高于对照组(P<0.05)。术后1周,观察组的LVEF高于对照组,LVEDD、LVESD小于对照组(P<0.05)。术后1周,观察组的CK、CK-MB及LDH水平低于对照组(P<0.05)。观察组的PCI术后不良心血管事件总发生率低于对照组(P<0.05)。结论重组人尿激酶原联合替罗非班治疗急性心肌梗死PCI术患者效果明显,可改善心功能,降低患者PCI术后不良心血管事件发生率。
Objective To explore the clinical effect of recombinant human prourokinase combined with tirofiban in the treatment of patients with acute myocardial infarction undergoing percutaneous coronary intervention(PCI).Methods A total of 100 patients with acute myocardial infarction undergoing PCI in our hospital from May 2021 to May 2022 were selected and divided into control group and observation group according to the difference of treatment plan,with 50 cases in each group.The control group was treated with PCI+conventional drugs+tirofiban,and the observation group was treated with recombinant human prourokinase on the basis of the control group.The clinical efficacy,cardiac function indexes[left ventricular ejection fraction(LVEF),left ventricular end-diastolic dimeter(LVEDD),left ventricular end-systolic dimeter(LVESD)],myocardial enzyme indexes[creatine kinase(CK),creatine kinase isoenzyme(CK-MB),lactate dehydrogenase(LDH)]and adverse cardiovascular events after PCI were compared between the two groups.Results The total effective rate of treatment in the observation group was higher than that in the control group(P<0.05).One week after operation,the LVEF in the observation group was higher than that in the control group,and the LVEDD and LVESD were smaller than those in the control group(P<0.05).One week after operation,the levels of CK,CK-MB and LDH in the observation group were lower than those in the control group(P<0.05).The total incidence of adverse cardiovascular events after PCI in the observation group was lower than that in the control group(P<0.05).Conclusion Recombinant human prourokinase combined with tirofiban is effective in the treatment of patients with acute myocardial infarction undergoing PCI,which can improve cardiac function and reduce the incidence of adverse cardiovascular events after PCI.
作者
黄毅
郑轶
HUANG Yi;ZHENG Yi(Xi'an People's Hospital/Xi'an Fourth Hospital,Xi'an 710004,China)
出处
《临床医学研究与实践》
2024年第31期62-66,共5页
Clinical Research and Practice
关键词
重组人尿激酶原
急性心肌梗死
经皮冠状动脉介入治疗
心功能
心肌酶
recombinant human prourokinase
acute myocardial infarction
percutaneous coronary intervention
cardiac function
myocardial enzyme
